BCL2L1

Across TCGA pan-cancer cohorts, BCL2L1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BCL2L1 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher BCL2L1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BCL2L1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where BCL2L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.299	0.755	.002	22	view →
HNSC	DFS	Quartile	IV	0.894	0.479	.001	19	view →
PDAC	OS	Quartile	II,III,IV	0.242	0.608	.013	10	view →
LUAD	DFS	Tertile	III,IV	0.399	0.873	.025	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BCL2L1–CCRCC (DFS)

Open the CCRCC breakdown →